MarketCapExport financials
Seres Therapeutics (MCRB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Seres Therapeutics Balance Sheet 2025-2011 | MCRB
Brief overview of Seres Therapeutics's balance sheet strength
The balance sheet is assessed across five available annual reports spanning 2019 to 2023.
Assets rose from $132.4 million to $358.6 million, a gain of +170.8%, while CAGR was about 28.3%. The balance sheet expanded rapidly.
Liability growth of +123.2% trailed asset growth of +170.8%. The funding structure became more resilient.
Negative shareholders' equity signals an accumulated net asset deficit and calls for particular caution.
Cash exceeds interest-bearing debt, producing net debt of -$11.3 million. The balance sheet therefore carries a net cash position.
The cash reserve occupies 35.7% of the balance sheet, previously 49.2%. It is one marker of short-term resilience.
The balance sheet carries negative retained earnings of -$978.2 million. The figure may result from accumulated losses or an active capital return policy.
Conclusion
Seres Therapeutics's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.
Annual Balance Sheet Seres Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
37.2 M | 60.8 M | -12.4 M | -109 M | -149 M | -85.9 M | -10.8 M | -78.6 M | -27.1 M | -54.5 M | -73.9 M | -112 M | -816 K | - | - |
Long Term Debt |
72.6 M | 83 M | 110 M | 50 M | 24.1 M | 25 M | 24.6 M | - | - | - | - | 1.3 M | 438 K | - | - |
Long Term Debt Current |
10.4 M | 8.67 M | 5.59 M | 3.6 M | 6.61 M | 5.12 M | 4.46 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
74.7 M | 84.8 M | 305 M | 252 M | 141 M | 122 M | 135 M | 126 M | 97.2 M | 110 M | 586 K | 139 M | 12.2 M | - | - |
Total Current Liabilities |
19.3 M | 41.2 M | 98.7 M | 85.6 M | 82.3 M | 46.4 M | 46 M | 42 M | 31.6 M | 30.5 M | 10.9 M | - | - | - | - |
Total Liabilities |
94 M | 126 M | 403 M | 338 M | 223 M | 168 M | 181 M | 169 M | 129 M | 140 M | 11.5 M | 144 M | 13.2 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | 25.8 M | 20.4 M | 12.1 M | 12.1 M | - | - | - | - | - |
Retained Earnings |
-972 M | -978 M | -978 M | -865 M | -614 M | -549 M | -460 M | -389 M | -264 M | -174 M | -82.6 M | -27.8 M | -11.1 M | - | - |
Total Assets |
138 M | 140 M | 359 M | 349 M | 355 M | 343 M | 132 M | 120 M | 190 M | 273 M | 217 M | 117 M | 2.12 M | - | - |
Cash and Cash Equivalents |
45.8 M | 30.8 M | 128 M | 163 M | 180 M | 116 M | 65.1 M | 85.8 M | 36.1 M | 54.5 M | 73.9 M | 114 M | 1.65 M | - | - |
Book Value |
44.2 M | 13.8 M | -44.9 M | 10.8 M | 132 M | 175 M | -48.3 M | -48 M | 60.7 M | 133 M | 205 M | -26.7 M | -11.1 M | - | - |
Total Shareholders Equity |
44.2 M | 13.8 M | -44.9 M | 10.8 M | 132 M | 175 M | -48.3 M | -48 M | 60.7 M | 133 M | 205 M | -26.7 M | -11.1 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Seres Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
23.1 M | 44.8 M | 69.6 M | 72.6 M | 75.3 M | 78 M | 80.5 M | 83 M | 85.3 M | 101 M | 103 M | 91.7 M | 105 M | 107 M | 107 M | 108 M | 17.8 M | - | 20.3 M | 18 M | 12.2 M | 13.8 M | 9.19 M | 10.6 M | 11.9 M | 13.2 M | 14.4 M | 15.7 M | 16.8 M | 18 M | 19.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
23.6 M | 47 M | 71.8 M | 74.7 M | 77.3 M | 79.9 M | 82.4 M | 84.8 M | 90 M | 301 M | 303 M | 305 M | 304 M | 306 M | 254 M | 252 M | 162 M | - | 157 M | 141 M | 126 M | 112 M | 114 M | 122 M | 122 M | 122 M | 128 M | 135 M | 114 M | 121 M | 135 M | 126 M | 101 M | 109 M | 114 M | 97.2 M | 99.3 M | 103 M | 106 M | 110 M | 112 M | 111 M | 110 M | 586 K | - | 727 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
44.5 M | 67.1 M | 91.1 M | 94 M | 99.8 M | 111 M | 114 M | 126 M | 155 M | 409 M | 401 M | 403 M | 383 M | 384 M | 318 M | 338 M | 244 M | - | 239 M | 223 M | 221 M | 169 M | 162 M | 168 M | 168 M | 166 M | 172 M | 181 M | 156 M | 164 M | 177 M | 169 M | 140 M | 146 M | 149 M | 129 M | 126 M | 128 M | 133 M | 140 M | 144 M | 139 M | 135 M | 11.5 M | 4.85 M | 6.37 M | 11.5 M | 7.99 M | 7.99 M | 7.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.78 M | 5.65 M | 4.86 M | 4.83 M | 1.79 M | 2.69 M | 2.77 M | 20.4 M | 17.9 M | 18 M | - | 12.1 M | 12.1 M | 12.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1 B | -988 M | -992 M | -972 M | -957 M | -965 M | -945 M | -978 M | -962 M | -1.05 B | -1.02 B | -978 M | -937 M | -889 M | -936 M | -865 M | -796 M | - | -671 M | -614 M | -564 M | -633 M | -584 M | -549 M | -531 M | -500 M | -480 M | -460 M | -441 M | -424 M | -414 M | -389 M | -368 M | -346 M | -318 M | -264 M | -235 M | -228 M | -200 M | -174 M | -149 M | -130 M | -102 M | -82.6 M | -63 M | -48.4 M | -82.6 M | -27.8 M | -27.8 M | -27.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
65.9 M | 102 M | 118 M | 138 M | 143 M | 144 M | 164 M | 140 M | 179 M | 322 M | 341 M | 359 M | 368 M | 406 M | 270 M | 349 M | 312 M | - | 320 M | 355 M | 396 M | 270 M | 306 M | 343 M | 356 M | 101 M | 111 M | 132 M | 124 M | 146 M | 107 M | 120 M | 109 M | 133 M | 159 M | 190 M | 212 M | 216 M | 245 M | 273 M | 298 M | 306 M | 324 M | 217 M | 227 M | 101 M | 217 M | 117 M | 117 M | 117 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
20.7 M | 17.8 M | 38.5 M | 54.4 M | 56.3 M | 54 M | 67.5 M | 39.5 M | 76.7 M | 81.1 M | 120 M | 136 M | 178 M | 238 M | 103 M | 171 M | 214 M | 135 M | 161 M | 188 M | 227 M | 74 M | 66.6 M | 116 M | 207 M | 61.5 M | 54.9 M | 65.1 M | 49.4 M | 102 M | 53.7 M | 85.9 M | 57.2 M | 59.5 M | 48.7 M | 36.2 M | 47.5 M | 35.2 M | 43.3 M | 55.9 M | 55.6 M | 59.8 M | 193 M | 75.5 M | 69.7 M | 36.3 M | 73.9 M | 114 M | 114 M | 114 M | - | 1.65 M | - | - | - | 6.22 M | - | - | - | - | - | - | - |
Book Value |
21.4 M | 34.5 M | 26.5 M | 44.2 M | 43.7 M | 33 M | 50.5 M | 13.8 M | 23.9 M | -87.1 M | -59.7 M | -44.9 M | -15.1 M | 22.6 M | -47.9 M | 10.8 M | 67.6 M | - | 81 M | 132 M | 176 M | 101 M | 144 M | 175 M | 188 M | -65.6 M | -61.6 M | -48.3 M | -32.2 M | -18 M | -69.8 M | -48 M | -30.6 M | -13.3 M | 10 M | 60.7 M | 85.5 M | 87.9 M | 111 M | 133 M | 154 M | 167 M | 190 M | 205 M | 222 M | 94.9 M | 205 M | 109 M | 109 M | 109 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
21.4 M | 34.5 M | 26.5 M | 44.2 M | 43.7 M | 33 M | 50.5 M | 13.8 M | 23.9 M | -87.1 M | -59.7 M | -44.9 M | -15.1 M | 22.6 M | -47.9 M | 10.8 M | 67.6 M | 23.1 M | 81 M | 132 M | 176 M | 101 M | 144 M | 175 M | 188 M | -65.6 M | -61.6 M | -48.3 M | -32.2 M | -18 M | -69.8 M | -48 M | -30.6 M | -13.3 M | 10 M | 60.7 M | 85.5 M | 87.9 M | 111 M | 133 M | 154 M | 167 M | 190 M | 205 M | 222 M | 94.9 M | 205 M | -26.7 M | -26.7 M | -26.7 M | - | -11.1 M | - | - | - | -4.35 M | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Seres Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Spain
Germany
Australia
Britain
